Martin et al. (2011) revealed that prostate epithelial Pten/TP53 loss leads to epithelial to mesenchymal transition. TP53 mutation is linked to a higher level of tumor-infiltrating T cells, which influences the immunotherapy response in prostate cancer (Kaur et al., 2019). Mu et al. (2017) reported that PTEN loss with TP53 mutation causes resistance to antiandrogen therapy of PCa. In addition, Jiang et al. (2018) demonstrated that TP53 mutation could result in an immunosuppressed state in gastric cancer. Here, PTEN is linked to prostate cancer.